
|Articles|December 1, 2001
Multidrug regimen boosts responses to bexarotene
Response rates to bexarotene in patients with cutaneousT-cell lymphoma can be improved with the use of combination therapy
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement


















